Healthcare Stocks to Watch: Catalyst Pharmaceuticals, AVITA Medical, and Moleculin Biotech.

The article highlights three health care stocks that are oversold and may be undervalued, based on the Relative Strength Index (RSI). Catalyst Pharmaceuticals (CPRX) has an RSI of 27.5, AVITA Medical (RCEL) has an RSI of 24.2, and Moleculin Biotech (MBRX) has an RSI of 21.4. These stocks have fallen in recent months and have a 52-week low, presenting an opportunity to buy into undervalued companies.

Healthcare stocks have been experiencing volatility, with several companies showing signs of being oversold according to the Relative Strength Index (RSI). This article highlights three healthcare stocks—Catalyst Pharmaceuticals (CPRX), AVITA Medical (RCEL), and Moleculin Biotech (MBRX)—that are currently trading at or near their 52-week lows, presenting potential opportunities for investors.

Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals reported better-than-expected quarterly earnings on May 7, with the company's stock falling around 13% over the past month and reaching a 52-week low of $14.75. The RSI for CPRX is currently at 27.5, indicating the stock is oversold. Despite the recent drop, the company's Edge Stock Ratings show a momentum score of 81.89 and a value score of 60.40, suggesting a potential rebound [1].

AVITA Medical (RCEL)

AVITA Medical reported its first-quarter financial results on May 8, missing its EPS and sales estimates. The company's stock fell around 21% over the past month and has a 52-week low of $4.71. With an RSI of 24.2, RCEL is also considered oversold. Benzinga Pro's charting tool identified a trend in RCEL stock, indicating a potential recovery [1].

Moleculin Biotech (MBRX)

Moleculin Biotech announced a $5.9 million public offering of 16,080,000 shares and Series E warrants on June 20. The company's stock fell around 58% over the past five days and has a 52-week low of $0.25. The RSI for MBRX is 21.4, indicating an oversold condition. Despite the recent decline, analysts forecast a substantial upside potential for MBRX, with an average target price of $9.33, indicating a dramatic potential upside of 2,950.11% from the current trading price of $0.31 [2].

Conclusion

Investors should be cautious when considering these healthcare stocks. While the RSI indicates oversold conditions, past performance is not indicative of future results. It is essential to conduct thorough due diligence and consider other fundamental factors before making investment decisions.

References

[1] https://www.benzinga.com/trading-ideas/long-ideas/25/06/46113313/top-3-health-care-stocks-youll-regret-missing-this-quarter-
[2] https://www.gurufocus.com/news/2937061/moleculin-biotech-mbrx-shares-decline-on-new-offerings